On Thursday, Axiall Corp (NYSE:AXLL)’s shares inclined 6.23% to $37.70.
Axiall Corp (AXLL) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front. Recently, the 50 Day Moving Average for AXLL broke out below the 200 Day Simple Moving Average, suggesting short-term bearishness.
This has already started to take place, as the stock has moved lower by 6.4% in the past four weeks. And with the recent moving average crossover, investors have to think that more unfavorable trading is ahead for AXLL stock.
If that wasn’t enough, Axiall isn’t looking too great from an earnings estimate revision perspective either. It appears as though many analysts have been reducing their earnings expectations for the stock lately, which is usually not a good sign of things to come.
Axiall Corporation manufactures and markets chemicals and building products in the United States and internationally. The company operates through three segments: Chlorovinyls, Building Products, and Aromatics. The Chlorovinyls segment produces chlor-alkali and derivative products, counting chlorine, caustic soda, vinyl chloride monomer, and vinyl resins; other chlor-alkali and derivative products comprising chlorinated ethylene, calcium hypochlorite, hydrochloric acid, and phosgene derivatives; and compound products, such as vinyl compounds, and compound additives and plasticizers.
Atossa Genetics Inc (NASDAQ:ATOS)’s shares dropped -1.53% to $1.29.
Atossa Genetics Inc (ATOS) declared it priced an offering to raise about $6,220,000 through the sale of about 1.83 million shares of common stock and pre-funded warrants to acquire about 3.61 million additional shares of common stock. The offering has been made to two institutional healthcare investors, with the shares being sold at a price of $1.15 per share, and the pre-funded warrants being sold at a price of $1.14 per warrant, payable at closing.
Roth Capital Partners served as lead placement agent for the offering. Dawson James Securities, Inc. served as co-placement agent for the offering. After placement agent fees and estimated offering expenses payable by the company, the company anticipates to receive net proceeds of about $5.6 million. The offering is predictable to close on or about June 10, 2015, subject to customary closing conditions.
Atossa intends to use the net proceeds from the offering for general corporate purposes, funding its future clinical trials and for general and administrative expenses.
At the end of Thursday’s trade, salesforce.com, inc. (NYSE:CRM)‘s shares dipped -0.86% to $72.40.
salesforce.com, inc. (CRM) the biggest cloud computing software company, was approached by a potential buyer. These rumors are assisting to boost the value of Salesforce’s stock which has been trading at all time highs over the past month.
Although the company has been unprofitable for a number of years now, it has been able to maintain investor confidence due to its extremely fast growth. This impressive growth backed by investor confidence means that Salesforce can demand a high takeover premium. However, the precise amount of that premium is a subjective matter dependent upon differing views on the potential for future growth, the company’s ability to start earning profits, and its ability to sustain them in the long run.
salesforce.com, inc. provides enterprise cloud computing solutions, with a focus on customer relationship administration to various businesses and industries worldwide. The company offers enterprise cloud computing apps and platform services, counting Sales Cloud for sales force automation, which enables companies to store data, access accurate customer and prospect information, track leads and progress, forecast opportunities, and collaborate around any sale on desktop and mobile devices; Service Cloud that enables companies to connect address customers service and support needs; and Marketing Cloud, which enables companies to map customer journeys to digital marketing interactions through email, mobile, social, Web, and connected products.
Immunomedics, Inc. (NASDAQ:IMMU), ended its Thursday’s trading session with -8.68% loss, and closed at $4.21.
Immunomedics, Inc. (IMMU) declared an interim analysis of a mid-stage clinical study showed that its first-in-class antibody-drug conjugate (ADC), labetuzumab govitecan, produced encouraging survival results in patients formerly treated with at least one prior irinotecan-containing regimen for their metastatic colorectal cancer (mCRC).
For the 33 patients who received the ADC at the 8 or 10 mg/kg dose levels, the interim median progression-free survival (PFS), a measure of the length of time the patient is living without their disease getting worse from the starting of their labetuzumab govitecan treatments, was 4.4 months, with 22% of these patients still benefiting from their cancer not progressing.
Immunomedics, Inc., a biopharmaceutical company, focuses on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune, and other diseases in the United States. Its clinical programs comprise epratuzumab, which is in two Phase III clinical trials for the treatment of lupus; and Yttrium-90 labeled clivatuzumab tetraxetan that is in Phase 3 registration study for the treatment of pancreatic cancer.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
